Vitamin B6-Dependent Epilepsies

Vitamin B6-dependent epilepsies are a small but clinically important group of genetic metabolic epilepsies in which seizures depend on disturbances of vitamin B6 metabolism or function. They are especially important because some affected newborns and infants have severe seizures that respond poorly to ordinary antiseizure medicines but can improve dramatically when the correct form of vitamin B6 is given.

The term does not describe one disease. The best-established genetic causes include PDE-ALDH7A1, PNPO deficiency and PLPBP deficiency. Other disorders can also produce pyridoxine- or pyridoxal-5′-phosphate-responsive seizures.

Why vitamin B6 matters to the brain

Vitamin B6 exists in several related chemical forms, sometimes called vitamers. Pyridoxal 5′-phosphate (PLP) is the biologically active cofactor used by many enzymes.

In the nervous system, PLP is required for biochemical reactions involved in amino-acid metabolism and the synthesis or breakdown of several neurotransmitters. If PLP cannot be produced, maintained or used normally, brain electrical activity can become severely disrupted.

The three major genetic disorders are not the same

PDE-ALDH7A1

In pyridoxine-dependent epilepsy due to ALDH7A1 deficiency, the primary problem is lysine metabolism. Accumulated metabolites, especially P6C, inactivate PLP and create a secondary functional vitamin B6 deficiency within affected biochemical pathways.

Seizures usually respond to pharmacological pyridoxine, but modern treatment also considers lysine-reduction therapy because pyridoxine does not remove the underlying toxic metabolite burden.

Read the full guide: Pyridoxine-Dependent Epilepsy (ALDH7A1) →

PNPO deficiency

PNPO encodes pyridox(am)ine 5′-phosphate oxidase, an enzyme required to produce PLP from other vitamin B6 forms. When PNPO activity is severely reduced, the brain can become deficient in active PLP even when ordinary vitamin B6 is present.

GeneReviews reports that most affected people present with seizures in the neonatal period, although later-onset disease occurs. Seizures are usually resistant to conventional antiseizure medicines. Around 60% of reported affected individuals respond to lifelong PLP treatment, while around 40% respond to pyridoxine.

That difference is clinically important: the name “vitamin B6-dependent epilepsy” does not tell clinicians which B6 vitamer will be most effective.

PLPBP deficiency

PLPBP encodes a protein involved in maintaining PLP homeostasis. Biallelic pathogenic variants can cause a treatable early-onset epileptic encephalopathy, usually beginning in the neonatal period.

Affected seizures may respond rapidly to either pyridoxine or PLP, but many people still require additional antiseizure medicines. Developmental outcome is variable, ranging from normal development to significant learning, speech or motor difficulties.

Why early recognition matters

Severe neonatal seizures can have many causes: structural brain injury, infection, hypoxic-ischaemic injury, genetic channel disorders, metabolic disease and others. Vitamin B6-dependent epilepsies are particularly important because delayed targeted treatment may prolong uncontrolled seizures during a critical period of brain development.

GeneReviews notes that diagnostic delay and prolonged periods of uncontrolled seizures are associated with greater neurodevelopmental impairment in PNPO deficiency. Early targeted treatment is also emphasised in PLPBP deficiency.

What do the seizures look like?

There is no single diagnostic seizure appearance. Reported seizure types include tonic, clonic, myoclonic, focal and bilateral convulsive seizures, epileptic spasms and status epilepticus.

EEG findings can also vary, including multifocal abnormalities, burst suppression, reduced background activity or other epileptiform patterns. A normal or non-specific early EEG does not by itself exclude a vitamin B6-dependent disorder.

A response to vitamin B6 does not identify the gene

Pyridoxine or PLP responsiveness is an important clinical clue, but several different genetic and metabolic disorders can show a response. The same individual disorder can also respond differently from one person to another.

Modern diagnosis therefore combines a carefully monitored treatment trial where appropriate with biochemical testing and genomic analysis rather than relying on “the seizures stopped with B6” as the final diagnosis.

Why withdrawal testing is no longer a simple diagnostic strategy

Historically, clinicians sometimes stopped vitamin B6 and waited for seizures to recur to prove dependency. Current GeneReviews guidance for PLPBP deficiency specifically advises against diagnostic withdrawal in neonates and young infants while molecular testing is pursued.

Once a vitamin B6-dependent epilepsy is strongly suspected and treatment is controlling seizures, deliberately provoking recurrence can expose the infant to unnecessary neurological risk.

Biochemical tests can help separate the disorders

PDE-ALDH7A1 has characteristic lysine-pathway biomarkers such as elevated α-aminoadipic semialdehyde. PNPO and PLPBP deficiencies have different biochemical signatures, although abnormalities can overlap and may be influenced by treatment.

Because specialised assays are not universally available, genomic testing has become increasingly important in confirming the exact cause.

Genetic testing

All three major disorders are usually caused by pathogenic variants affecting both copies of the relevant gene and are typically inherited in an autosomal-recessive manner.

Testing may be performed using a neonatal or developmental-and-epileptic-encephalopathy panel, an epilepsy panel, exome sequencing or genome sequencing. The most appropriate route depends on the clinical situation and local laboratory system.

The first dose can require intensive monitoring

High-dose pyridoxine or PLP is not an ordinary nutritional supplement in this setting. Initial treatment can cause marked somnolence, apnoea, respiratory insufficiency or other cardiorespiratory depression in some infants.

For suspected severe neonatal vitamin B6-dependent epilepsy, the initial diagnostic treatment is therefore performed in an appropriately monitored clinical setting with respiratory support available.

Long-term treatment is diagnosis-specific

PDE-ALDH7A1 usually requires lifelong pyridoxine and may also require specialist lysine-reduction therapy. PNPO deficiency may be treated lifelong with PLP or pyridoxine depending on response. PLPBP deficiency is also treated with lifelong vitamin B6 therapy, using pyridoxine or PLP according to individual response and tolerance.

These pharmacological doses can have adverse effects. Pyridoxine can cause peripheral neuropathy with excessive chronic exposure, while high-dose PLP requires monitoring for potential liver toxicity. The lowest effective specialist-prescribed dose is therefore used rather than treating “more B6” as automatically better.

Ordinary supplements are not a substitute

These disorders are caused by genetic defects in metabolic pathways, not by an inadequate diet. Eating vitamin-B6-rich foods or taking a standard multivitamin cannot substitute for diagnosis-specific pharmacological treatment.

Conversely, giving very large over-the-counter doses of vitamin B6 to someone with unexplained seizures can cause harm and may also complicate subsequent diagnostic testing.

Developmental outcome

Rapid seizure control does not guarantee normal neurodevelopment. Developmental delay, speech and language difficulties, intellectual disability, hypotonia or movement disorders can persist in some affected people.

Outcome depends on the specific disorder, genetic variant, prenatal effects, duration of uncontrolled seizures and timing of targeted treatment. Ongoing developmental assessment remains important even when seizures are well controlled.

Worldwide access

These are treatable disorders, but diagnosis depends on clinicians recognising them and having access to monitored neonatal treatment, biochemical assays and genomic testing. Those services are highly uneven worldwide.

Pyridoxine itself may be inexpensive, yet the correct diagnosis can still be missed where neonatal EEG, intensive monitoring, rare-metabolic testing or rapid genetic sequencing is unavailable. PLP formulations and specialist follow-up may also be difficult to obtain in some countries.

Full disorder guides

PNPO Deficiency and Epilepsy →
PLPBP Deficiency and Epilepsy →
Pyridoxine-Dependent Epilepsy (ALDH7A1) →

The central point

“Vitamin B6-dependent epilepsy” is a treatment clue, not a complete diagnosis. ALDH7A1, PNPO and PLPBP disorders affect different biochemical pathways and can require different forms of vitamin B6, additional metabolic treatment and different monitoring. Early specialist recognition and molecular diagnosis matter.

Sources

Medical note: pharmacological pyridoxine and PLP are medical treatments. High-dose vitamin B6 should not be used as a home diagnostic test or started, stopped or switched without specialist clinical supervision.

Evidence checked: September 2026.